Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-a651c9ffaada5f4880461c8764acc607"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-a651c9ffaada5f4880461c8764acc607"/>
<resource>
<Composition>
<id value="composition-en-a651c9ffaada5f4880461c8764acc607"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-a651c9ffaada5f4880461c8764acc607"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-a651c9ffaada5f4880461c8764acc607</b></p><a name="composition-en-a651c9ffaada5f4880461c8764acc607"> </a><a name="hccomposition-en-a651c9ffaada5f4880461c8764acc607"> </a><a name="composition-en-a651c9ffaada5f4880461c8764acc607-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/03/263/001-003</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - dukoral</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/03/263/001-003"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpa651c9ffaada5f4880461c8764acc607"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - dukoral"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet:</p><ol type="1"><li>What Dukoral is and what it is used for</li><li>What you need to know before you use Dukoral</li><li>How to use Dukoral</li><li>Possible side effects</li><li>How to store Dukoral</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What dukoral is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What dukoral is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Dukoral is an oral vaccine against cholera that stimulates the immunological defence in the gut. The vaccine protects adults and children from 2 years of age against cholera.</p><p>Dukoral causes your body to produce its own protection against cholera. After getting the vaccine, your body will make substances called antibodies, which fight the cholera bacteria and toxin that cause diarrhoea.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take dukoral"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take dukoral"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use Dukoral</p><ul><li>if you are allergic to any ingredient of the vaccine or to formaldehyde.</li><li>if you have an acute stomach disorder or infection with fever (vaccination should be delayed).</li></ul><p>Warnings and precautions Talk to your doctor before taking Dukoral if you take a medical treatment that affects the immune system<br/>if you have a disease of the immune system (including HIV infection).<br/>The vaccine may provide you with a lower level of protection than it does for people with healthy immune systems.</p><p>The vaccine does not provide complete protection and it is important to adhere to dietary and hygiene advice to avoid diarrhoeal diseases.</p><p>Children Do not give this vaccine to children younger than 2 years since the protection has not been studied in this group.</p><p>Other medicines and Dukoral Please tell your doctor if you are taking or have recently taken any other medicines. Do not take other medicine starting 1 hour before until 1 hour after taking the vaccine.<br/>Using Dukoral with food and drink Avoid food and drink starting 1 hour before until 1 hour after the vaccination.</p><p>Pregnancy and breast-feeding If you are pregnant, think you may be pregnant or are planning to have a baby or are breast-feeding, ask your doctor before taking the vaccine.</p><p>Driving and using machines There are no reasons to suspect that Dukoral will affect your ability to drive or handle machines</p><p>Dukoral contains sodium Dukoral contains approximately 1.1 g sodium per dose. Please take this into consideration if you are on a controlled sodium diet.</p></div>
</text>
</section>
<section>
<title value="3. How to take dukoral"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take dukoral"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always use this medicine exactly as described in this leaflet or as your doctor has told you. Check with your doctor if you are not sure. Adults and children from 6 years of age: The primary vaccination is 2 doses taken orally (by mouth) at least 1 week (up to 6 weeks) apart.<br/>Take the 1st dose no later than 2 weeks before you leave for your trip. Take the 2nd dose at least 1 week after the 1st dose and at least 1 week before your trip.<br/>It takes about 1 week after the last dose for protection to begin. For continuous protection, re-vaccination is recommended within 2 years. If you had your last dose of vaccine less than 2 years ago a single dose will renew your protection. If more than 2 years have passed since you had the last vaccine dose, the primary vaccination (2 doses) should be repeated.</p><p>Children of 2 to below 6 years of age: The primary vaccination is 3 doses taken orally (by mouth) at least 1 week (up to 6 weeks) apart. Only half of the amount of the buffer solution should be mixed with the vaccine.<br/>Give the 1st dose to the child no later than 3 weeks before you leave for your trip.<br/>Give the 2nd dose to the child at least 1 week after the 1st dose.<br/>Give the 3rd dose at least one week after the 2nd dose and at least one week before your trip.</p><p>It takes about 1 week after the last dose for protection to begin. For continuous protection, re-vaccination is recommended within 6 months. If less than 6 months have passed since the last vaccination a single dose will renew the protection. If more than 6 months have passed since the last vaccination, the primary vaccination (3 doses) should be repeated.</p><p>The suspensionsupplied in a single-dose glass vial is a whitish suspension. Each vial comes with one sachet package that contains a white effervescent powder of sodium hydrogen carbonate. The effervescent powder should be dissolved in a glass of cool water, and the resulting buffer solution should be mixed with the suspension. It is important to use the buffer solution, as it protects the vaccine from the gastric acid.</p><p>Drink the entire mixture within 2 hours after mixing with the buffer solution. Instructions for use:</p><ol type="1"><li><p>To prepare the buffer solution, dissolve the effervescent powder in a glass of cool water (approx. 150 ml) by gently stirring.<br/>Do not use any other liquid. For children of 2 to below6 years: pour away half of the buffer solution.</p></li><li><p>Shake the Dukoral suspension vial (1 vial = 1 dose).</p></li><li><p>Pour the content of the Dukoral suspension vial into the glass of buffer solution (see 1).<br/>Mix by gently stirring.</p></li><li><p>Drink the entire mixture within 2 hours. Avoid food and drink starting 1 hour before until 1 hour after drinking the mixture.</p></li></ol><p>If you take more Dukoral than you should If you take the doses less than one week apart, contact your doctor, pharmacist or nurse. Because each vial of Dukoral contains only one dose, overdosage is unlikely.<br/>If you have taken more than one dose at one time, please contact your doctor, pharmacist or nurse. If you forget to take Dukoral. You can take the 2nd dose of Dukoral up to 6 weeks after the 1st dose (children of 2 to below 6 years have to take 3 doses). If more than 6 weeks have passed, contact your doctor, pharmacist or nurse.</p><p>If you have any further questions on the use of this vaccine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, Dukoral can cause side effects, although not everybody gets them. Contact a doctor immediately if you experience the following serious side effects: severe diarrhoea with loss of water from the body<br/>serious allergic reactions causing swelling of the face or throat and breathlessness</p><p>Other side effects: Uncommon side effects (may affect up to 1 in a 100 people)<br/>Diarrhoea, stomach pain, stomach cramps, gurgling stomach, bloated stomach, stomach gas and general stomach discomfort<br/>Headache</p><p>Rare side effects (may affect up to 1 in a 1,000 people) Fever Generally feeling unwell, feeling dizzy<br/>Nausea (feeling sick), vomiting, loss of /or poor appetite Swelling irritation inside the nose, and cough.</p><p>Very rare side effects (may affect up to 1 in a 10,000 people)<br/>Rash<br/>Sore throat, reduced sense of taste Fatigue/feeling tired<br/>Sweating, shivering Joint pain Difficulty in sleeping</p><p>Other side effects (frequency cannot be estimated from the available data) Flu -like symptoms, chestiness, chills, general pain, weakness Hives, itching Swelling of the lymph glands Numbness or pins and needles High blood pressure</p><p>Reporting of side effects If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V*. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store dukoral"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store dukoral"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children. Do not use Dukoral after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2 C 8 C). Do not freeze.</p><p>Product in the unopened vial and sachet, stored in the outer carton, is stable at temperatures up to 25oC for a period of 14 days. At the end of this period the product should be used or discarded.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Dukoral contains</p><ul><li><p>The active substances are: 31.25x109 bacteria* of each of the following V. cholerae O1 strains: Inaba classical biotype (heat inactivated), Inaba El Tor biotype (formalin inactivated), Ogawa classical biotype (heat inactivated), Ogawa classical biotype (formalin inactivated).<br/>Recombinant cholera toxin B subunit (rCTB) 1 mg. *bacterial content prior to inactivation</p></li><li><p>The other ingredients in the vaccine suspension are sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride and water for injections.</p></li><li><p>The effervescent powder contains sodium hydrogen carbonate, citric acid, sodium carbonate, saccharin sodium, sodium citrate and raspberry flavour.</p></li></ul><p>What Dukoral looks like and contents of the pack Dukoral is presented as a suspension and effervescent powder for oral suspension. The suspension is a whitish suspension supplied in a vial. The effervescent powder is white with a raspberry flavour and is supplied in a sachet.</p><p>Dukoral is available in packs of 1, 2 and 20 doses. Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder<br/>Valneva Sweden AB, 105 21 Stockholm, Sweden.<br/><a href="mailto:infodukoral@valneva.com">infodukoral@valneva.com</a></p><p>Manufacturer Valneva Sweden AB, Gunnar Asplunds all 16, SE-171 69 Solna, Sweden.</p><p>This leaflet was last revised in MM/YYYY</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpa651c9ffaada5f4880461c8764acc607"/>
<resource>
<MedicinalProductDefinition>
<id value="mpa651c9ffaada5f4880461c8764acc607"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpa651c9ffaada5f4880461c8764acc607"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpa651c9ffaada5f4880461c8764acc607</b></p><a name="mpa651c9ffaada5f4880461c8764acc607"> </a><a name="hcmpa651c9ffaada5f4880461c8764acc607"> </a><a name="mpa651c9ffaada5f4880461c8764acc607-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/03/263/001-003</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Dukoral suspension and effervescent powder for oral suspension</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/03/263/001-003"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="Dukoral suspension and effervescent powder for oral suspension"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
